BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:The HIV glycan shield as a target for broadly neutralizing antibod
 ies - Dr Katie Doores\, MRC Career Development Fellow\, Department of Infe
 ctious Diseases\, King's College London 
DTSTART:20181003T150000Z
DTEND:20181003T160000Z
UID:TALK108799@talks.cam.ac.uk
CONTACT:Fiona Roby
DESCRIPTION:The elicitation of broadly neutralizing antibodies (bnAbs) is 
 a key step for the development of a successful an HIV vaccine. Approximate
 ly 10-30% of HIV infected individuals do elicit broadly neutralizing antib
 odies that have been shown to protect against infection in macaque models.
  Isolation and epitope characterization of these antibodies reveal conserv
 ed regions of the virus envelope that can be targeted through vaccine desi
 gn. The HIV envelope glycoprotein\, gp120\, is one of the most heavily gly
 cosylated proteins known. The high density of glycans on gp120 limits thei
 r processing during biosynthesis\, leading to the formation of a high-mann
 ose patch on gp120. The density and heterogeneity of the glycans impede ne
 utralizing antibody (NAb) recognition of Env but\, paradoxically\, some of
  the most potent broadly active bNAbs recognize epitopes involving this gl
 ycan shield. Here I will discuss our recent studies on the characterizatio
 n of the HIV glycan shield and the development of HIV glycan-binding HIV b
 nAbs in a longitudinal cohort of HIV infected individuals.
LOCATION:Lecture Theatre 2\, Department of Veterinary Medicine
END:VEVENT
END:VCALENDAR